LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Nexcella an $8 million CLIN2 grant award to support clinical development of its chimeric antigen receptor T cell (CAR-T) therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis. “AL amylo ...

IND follows encouraging findings of necrosis, inflammation and T cell infiltration in tumor biopsy of patient in lowest dose cohortSAN JOSE, Calif., July 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Moffitt Cancer Center (Moffitt), has received approval by the U.S. Food and Drug Administration (FDA) of an individual patient Investigational New Drug ...

Kirpal Kooner The opportunity The investment thesis in CAPREIT (TSX:CAR.UN:CA) concerns the Canadian housing sector and its current affordability crisis. A specific mix of demographic, regulatory, and economic conditions has aligned to create a favorable environment for residential rental properties and apartment REITs. The demographic tailwind There is a saying in Canada that it takes five minutes for a family to arrive in Canada, and seven years for the country to build them a home. According to Stati ...

Two-storey residential building in Ottawa, Canada Iryna Tolmachova/iStock Editorial via Getty Images Note: All amounts discussed are in Canadian Dollars. Securities discussed trade primarily on Canadian exchanges. Canadian options are not accessible by US investors. On our last venture out into analyzing Canadian Apartment Properties Real Estate Investment Trust (TSX:CAR.UN:CA), we upgraded the REIT to a Buy and after staying on the sidelines for about 18 months. Right or wrong, we prefer to make calls ba ...

PARSIPPANY, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ:CAR) announced today that it plans to report its second quarter 2024 results after the market close on Monday, August 5th, 2024, and to host a conference call for institutional investors to discuss these results on Tuesday, August 6th, 2024 at 8:30 a.m. Eastern time. Investors may access the call at ir.avisbudgetgroup.com, or by dialing (877)-407-2991. Investors are encouraged to dial in approximately 10 minutes prior to the ...

PARSIPPANY, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its second quarter 2024 results after the market close on Monday, August 5th, 2024, and to host a conference call for institutional investors to discuss these results on Tuesday, August 6th, 2024 at 8:30 a.m. Eastern time. Investors may access the call at ir.avisbudgetgroup.com, or by dialing (877)-407-2991. Investors are encouraged to dial in approximately 10 minutes prior to th ...

Lead site Memorial Sloan Kettering Cancer Center (MSKCC)Timing of milestone in-line with mid-2024 guidanceData from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the 1st patient has been dosed at MSKCC in its U.S. ...

文章核心观点 - 加州再生医学研究所(CIRM)向生物科技公司Senti Bio授予800万美元的资助,用于支持SENTI-202 CAR-NK细胞疗法的临床开发,该疗法有望成为治疗复发/难治性血液恶性肿瘤(包括急性髓系白血病)的首创性疗法 [1][2][3] - SENTI-202是一种Logic Gated CAR-NK细胞疗法,设计用于有选择性地靶向和消除表达CD33和/或FLT3的血液恶性肿瘤细胞,同时保护健康的骨髓细胞 [3] - 急性髓系白血病是一种严重的血液和骨髓癌症,目前的治疗方法包括化疗、靶向疗法和干细胞移植,但对于复发或难治性患者的预后仍然很差 [5] - Senti Bio正在开发一系列基于基因电路的细胞和基因疗法,利用CAR-NK细胞靶向各种液体和实体肿瘤 [6][7] 公司概况 - Senti Bio是一家专注于开发新一代细胞和基因疗法的生物技术公司,利用合成生物学平台"基因电路"来增强疗法的精准性和可控性 [6] - 公司的管线包括多种基于CAR-NK细胞的疗法,针对各种血液和实体肿瘤 [6][7] - 公司还与Spark Therapeutics和BlueRock Therapeutics建立了合作关系,探索基因电路在其他疾病领域的应用 [7] 行业概况 - 急性髓系白血病是成人最常见的急性白血病,预后较差,5年生存率约为30% [5] - 目前的治疗方法包括化疗、靶向疗法和干细胞移植,但对于复发或难治性患者的治疗选择有限,预后通常不到7个月 [5] - 细胞和基因疗法是新兴的治疗方法,有望为恶性肿瘤患者提供更好的治疗选择 [6]

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination triggers a $2 million milestone payment to CarismaPHILADELPHIA, June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ("Development Candidate"), under its collaboration ...

Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; ...